On Wednesday Zosano Pharma Corporation (NASDAQ:ZSAN) stock traded volume of 1144180 shares during its last trading session as compared to its average volume of 264833 shares over the recent month. ZSAN ended its day with the positive stream along the move of 22.37% and closed at the price of $1.86 before opening at $1.55. It has total market capitalization is $33909660. 52week range of the stock remained $ 1.41 – 6.65 while its day lowest price was $1.54 and its hit its day highest price at $1.94.
On Nov. 27, 2019, Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company, revealed that it has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate of 2,181,034 shares of its common stock at a price of $1.45 per share in a registered direct offering.
Zosano intends to use the net proceeds from the offering to fund pre-approval commercialization activities, including submitting its NDA for Qtrypta™ (M207) for the treatment of migraine, and for general working capital and corporate purposes.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on developing products where rapid administration of molecules with demonstrated safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s Adhesive Dermally-Applied Microarray (ADAM) technology consists of titanium microneedles coated with drug that can enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is QtryptaTM (M207), which is a proprietary formulation of zolmitriptan delivered via ADAM technology, as an acute treatment for migraine. The company is preparing to submit a New Drug Application (NDA) to the Food and Drug Administration for QtryptaTM (M207). The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization.
Eugene Harris joined us after more than 10 years of experience in writing financial and business news, most recently as Investment Editor and writer. He also has a vast knowledge of stock trading. Eugene earned bachelor degree from Union College with a focus in Business Administration. Eugene is the Senior Editor and market movers section. He also holds an MBA from Penn State University He has two daughter and two children.
Email Contact – [email protected]
Address – 797 Paradise Crescent, Hauterive, Quebec
Zip Code – G5C 1M1
Phone Number – 418-920-9491